Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/2695
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSAIDOVA Shakhnoza Aripovna., MUSAYEVA Lola Jurayevna., ILKHAMOVA Zilola Erkindjanovna BAYKHANOVA Dilrabo Djamaliddinovna-
dc.date.accessioned2025-12-16T09:47:36Z-
dc.date.available2025-12-16T09:47:36Z-
dc.date.issued2025-
dc.identifier.urihttp://repo.tma.uz/xmlui/handle/1/2695-
dc.description.abstractLiver cirrhosis is a serious disease, being the 11th most frequent cause of death worldwide, with 50% of patients dying within 5 years. Ascites in cirrhosis develops as a result of various pathogenetic factors: hyperaldosteronism, fluid accumulation in the body, portal hypertension, increased lymph production and impaired outflow, reduced drainage function of the parietal peritoneum, autoimmune dysproteinemia, and disturbance of plasma colloid-oncotic balance. Modern medicine offers several methods for treating ascites, including drug therapy, serial laparocenteses with removal of large volumes of fluid, transjugular intrahepatic portosystemic shunts, implanted drainage devices, as well as acellular and concentrated reinfusion therapy. Each of these approaches has its advantages and limitations, and choosing the optimal treatment strategy often presents a challenging task. This article discusses modern methods of ascites treatment using reinfusion with the Fresenius preparation.en_US
dc.language.isoen_USen_US
dc.publisherO'zbekiston, Toshkenten_US
dc.subjectascitic fluid, albumin, liver cirrhosis, lymphatic system.en_US
dc.titlePATHOGENETIC RATIONALE FOR THE NECESSITY OF REINFUSION OF ASCITIC FLUID IN PATIENTS WITH LIVER CIRRHOSISen_US
dc.typeArticleen_US
Appears in Collections:

Files in This Item:
File Description SizeFormat 
14_JIGAR_SIRROZI_BILAN_OGā€˜RIGAN_BEMORLARDA_ASTSITIK_SUYUQLIKNI_.pdf979.54 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.